Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2020-04-28 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
独立董事对公司相关事项的独立意见
Governance Information Classification · 95% confidence The document is a detailed independent directors' opinion on various company matters including the 2019 profit distribution plan, internal control self-evaluation report, appointment of the audit firm for 2020, use of funds for short-term risk investment, external guarantees and related party transactions, and accounting policy changes. It references regulatory guidelines and company governance rules, and provides independent opinions on these corporate governance and financial matters. The document does not contain full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is not a simple announcement or certification but a substantive governance-related report by independent directors. This aligns best with the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices, including independent directors' opinions on key corporate matters.
2020-04-28 Chinese
关于召开2019年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2019 Annual General Meeting (AGM) of Beijing SL Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures (including online voting), agenda items to be discussed and voted on (such as the 2019 annual report, financial statements, profit distribution plan, appointment of auditors, and related party transactions), registration details, and proxy forms. The document does not contain the actual annual report or financial statements but rather serves as an official notification to shareholders about the AGM and the matters to be considered. The length is about 4748 characters, which is consistent with a detailed AGM notice. Therefore, this document fits the category of AGM Information (AGM-R).
2020-04-28 Chinese
2019年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for Beijing Shuanglu Pharmaceutical Co., Ltd. It includes detailed auditor opinions, audit basis, key audit matters, and extensive financial statements such as consolidated balance sheets, income statements, cash flow statements, and equity changes for the fiscal year ending December 31, 2019. The presence of an auditor's opinion, detailed audit procedures, and comprehensive financial data confirms this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters) and contains actual financial data and audit details, not just an announcement or certification. Therefore, the correct classification is Audit Report / Information (AR). FY 2019
2020-04-28 Chinese
独立董事魏素艳2019年度述职报告
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of Beijing Shuanglu Pharmaceutical Co., Ltd. for the year 2019. It includes comprehensive information about the director's attendance at board and shareholder meetings, independent opinions on various company matters including investment decisions, profit distribution, internal control evaluations, audit firm appointment, related party transactions, accounting policy changes, and governance issues. The document is lengthy (over 6,800 characters) and contains substantive content related to the company's governance and financial oversight for the year 2019. It is not a brief announcement or a certification letter but a full report on the independent director's duties and opinions for the year. This type of document fits best under the category of Board/Management Information (MANG), as it focuses on the independent director's report on board activities and governance matters rather than a full annual financial report (10-K) or audit report (AR).
2020-04-28 Chinese
独立董事苏志国2019年度述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2019 Annual Report" for Beijing SL Pharmaceutical Co., Ltd. It is a detailed report by an independent director summarizing their duties, attendance at board and shareholder meetings, opinions on various company matters including audit firm appointment, internal controls, related party transactions, accounting policy changes, and governance issues for the year 2019. The content is a comprehensive narrative of management and board oversight activities rather than a financial statement or audit report. It is not a full annual report (10-K) or audit report (AR), but rather a management/board related report focusing on the independent director's duties and opinions. This fits best under Board/Management Information (MANG) as it relates to board member activities and governance oversight. The document length (6949 characters) and detailed content support this classification with high confidence.
2020-04-28 Chinese
2019年年度报告摘要（已取消）
Annual Report Classification · 95% confidence The document is titled as the 2019 annual report summary of Beijing Shuanglu Pharmaceutical Co., Ltd. It contains detailed company information, business overview, product descriptions, industry status, and key financial data for multiple years including 2019. The content is comprehensive and includes financial performance metrics, business strategy, and operational details typical of an annual report. There is no indication that this is merely an announcement or a certification. The length (15,000 characters) and depth of content confirm it is the actual report, not just a notice or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2019
2020-04-28 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.